Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News report.faq_name
On This Report

Intrauterine Devices Market Size & Growth Forecast 2026–2035, By Segments (Type, Distribution Channel), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 13303| Published Date: May-2026| Format: PDF, Excel
MARKET OUTLOOK

Market Size and Growoth Outlook

Intrauterine Devices Market size stood at USD 6.65 Billion in 2025 and is predicted to grow at a 3.8% CAGR from 2026 to 2035, crossing USD 9.66 Billion by 2035. The industry revenue for 2026 is estimated at USD 6.86 billion.

Base Year Value (2025)
USD 6.65 Billion
CAGR (2026-2035)
3.8%
Forecast Year Value (2035)
USD 9.66 Billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035

Get more details on this report

Request Free Sample Report
SNAPSHOT

Intrauterine Devices Market Intelligence Snapshot

Regional Market Dynamics

  • North America leads due to established reproductive healthcare services, broad access to trained providers, and strong adoption of long-acting reversible contraception through clinical care settings.
  • Asia Pacific is projected to expand at a 4.33% CAGR, driven by improving women's healthcare access, wider contraceptive adoption, and expanding provider networks supporting family planning services.

Segment Momentum

  • Hormonal IUD held a 70.07% share in 2025, supported by widespread clinical familiarity and strong demand for reliable, long-acting, reversible contraception requiring minimal ongoing patient involvement.
  • Gynecology clinics are growing fastest because they provide specialized contraceptive counseling, insertion, and follow-up services, offering streamlined access that aligns well with routine IUD care and patient management.

Market Expansion Drivers

  • Government family planning initiatives increasing adoption of long-acting contraceptive solutions.
  • Rising awareness and education programs improving acceptance of intrauterine contraceptive devices.
  • Development of next-generation hormone-free IUDs expanding demand for advanced contraceptive options.

Leading Market Participants

FORECAST SNAPSHOT

Global Market Forecast Snapshot

Market Outlook

Prominent players in the intrauterine devices market include Bayer AG (Germany), CooperSurgical Inc. (United States), Pregna International Limited (India), EUROGINE, S.L. (Spain), OCON Medical Ltd. (Israel), Mona Lisa N.V. (Belgium), SMB Corporation of India (India), AbbVie Inc. (United States), DKT International (United States), Prosan International BV (Netherlands).

Regional and Segment Outlook

North America
MARKET DYNAMICS

Market Growth Drivers and Industry Trends

Government family planning initiatives increasing adoption of long-acting contraceptive solutions

Public family planning programs play a direct role in shaping procurement, clinical training, and patient access, which makes them a powerful force supporting expansion of the intrauterine devices market. When governments prioritize long-acting reversible contraception in national reproductive health strategies, IUDs become more available through public hospitals, primary care centers, and subsidized outreach services. This trends adoption from being dependent on individual provider preference or out-of-pocket affordability to being embedded in routine contraceptive counseling and supply systems, reinforcing market demand through larger institutional purchasing volumes and more consistent insertion rates.

Rising awareness and education programs improving acceptance of intrauterine contraceptive devices

Acceptance of IUDs is closely tied to how well patients understand safety, duration of protection, reversibility, and side-effect expectations, making education programs central to market adoption. In the intrauterine devices market, awareness efforts aimed at women of reproductive age, community health workers, and clinicians help reduce hesitation that often comes from misinformation or outdated perceptions around insertion, fertility impact, or suitability. As counseling becomes more informed and standardized, more women are willing to consider IUDs earlier in contraceptive decision-making rather than only after short-term methods fail, increasing market penetration through stronger conversion from consultation to procedure.

Development of next-generation hormone-free IUDs expanding demand for advanced contraceptive options

Innovation in hormone-free devices is broadening the addressable user base by responding to women who want long-duration contraception without hormone exposure. In the intrauterine devices market, next-generation hormone-free IUD development influences demand by improving the product mix available to gynecologists and family planning providers, especially for patients concerned about systemic hormonal effects or seeking nonhormonal reproductive health management. This expands choice at the point of care and gives manufacturers a clearer differentiation pathway, driving market development as clinical recommendations increasingly align with more personalized contraceptive selection.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Government family planning initiatives increasing adoption of long-acting contraceptive solutions 1.80% High Asia Pacific, Africa, Latin America High Near Term
Rising awareness and education programs improving acceptance of intrauterine contraceptive devices 1.50% Moderate Asia Pacific, Europe High Mid Term
Development of next-generation hormone-free IUDs expanding demand for advanced contraceptive options 1.30% High North America, Europe Emerging Mid Term
CUSTOM RESEARCH

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
REGIONAL FORECAST

Regional Demand Dynamics

Polymer Modified Bitumen Market
Largest Region
North America
XX% Market Share in 2025
North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest regional share of the intrauterine devices market in 2025, bolstered by established gynecological care pathways, broad availability of trained healthcare professionals, and routine access to contraceptive counseling through clinical settings. Market activity in the region is strengthened by higher awareness of long-acting reversible contraception and stronger integration of device-based birth control into standard reproductive health services, which helps sustain procedure volumes and replacement demand through hospitals, specialty clinics, and physician offices.

Asia Pacific is projected to expand at a 4.33% CAGR over the forecast period, with growth in the intrauterine devices market being impelled by improving access to women’s healthcare services and wider adoption of modern contraception across urban and semi-urban populations. Demand is accelerating as healthcare systems broaden reproductive care delivery and more patients enter formal clinical channels for family planning, creating practical momentum for device uptake through expanding provider networks and rising consultation rates.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants / Startups i Scale Sparse Moderate Dense
Macro Indicators i Scale Weak Stable Strong
COUNTRY INSIGHTS

Key Country Insights

Germany 🇩🇪

Clinical Care Integration

Germany prioritizes intrauterine device adoption through standardized gynecological care and evidence-based contraceptive practices. Healthcare providers in Germany continue integrating modern IUD options into preventive women's health services with a focus on long-term patient outcomes.

France 🇫🇷

Reproductive Care Accessibility

France supports intrauterine device utilization through comprehensive reproductive healthcare services and preventive care programs. Healthcare professionals in France continue encouraging informed contraceptive choices while expanding access to long-acting reversible contraceptive solutions.

Italy 🇮🇹

Gynecological Practice Support

Italy is advancing the intrauterine devices market by strengthening women's healthcare services and improving clinical adoption of long-term contraception. Italian healthcare providers emphasize patient consultation and reliable contraceptive solutions within routine gynecological practice.

Japan 🇯🇵

Personalized Contraceptive Care

Japan is gradually expanding the use of intrauterine devices by improving physician awareness and individualized contraceptive counseling. Medical providers in Japan are focusing on patient education and appropriate device selection for long-term reproductive health management.

South Korea 🇰🇷

Preventive Women's Healthcare

South Korea is strengthening the intrauterine devices market through broader reproductive health awareness and expanding access to modern contraceptive methods. Healthcare institutions in South Korea continue promoting clinician training and patient-centered family planning services.

United States 🇺🇸

Women's Health Innovation

The U.S. intrauterine devices market emphasizes expanding access to long-acting reversible contraception through advanced product options and broader provider adoption. Healthcare organizations in the U.S. continue supporting patient education and streamlined reproductive healthcare services.

SEGMENT ANALYSIS

Segment Leadership and Growth Trends

Intrauterine Devices Market Share (%), Type, 2025

Hormonal IUD
Copper IUD

Go beyond the chart, access full insights & data tables

Request Free Sample Report
Type Segment Analysis: Hormonal IUD (Largest & Fastest-Growing Segment)

Hormonal IUD held a 70.07% share of the intrauterine devices market in 2025, reflecting its established position in routine contraceptive care and its continued expansion across patient populations seeking long-acting, low-maintenance birth control. Its leadership in the intrauterine devices market is sustained by broad clinical familiarity and consistent adoption in provider-led contraceptive counseling, while its growth momentum comes from the same practical advantage that differentiates it from alternatives: strong alignment with demand for reliable, reversible contraception that fits long-duration use without requiring frequent patient action.

Distribution Channel Segment Analysis: Hospital (Largest Segment) vs Gynecology Clinics (Fastest-Growing Segment)

Hospital accounted for a 57.16% share of the intrauterine devices market in 2025, making it the leading distribution channel as IUD insertion and follow-up are often integrated into broader reproductive and women’s health services delivered in hospital settings. This share leadership is backed by the operational depth hospitals offer, including access to trained clinicians, procedural infrastructure, and coordinated care pathways that make them a primary setting for intrauterine device consultations and placements.

Gynecology Clinics are emerging as the fastest-growing distribution channel in the intrauterine devices market because they are closely aligned with specialized, appointment-driven contraceptive care. Their momentum relative to other channels is backed by focused women’s health services and more streamlined patient access for counseling, insertion, and follow-up, which fits the practical care model required for intrauterine device adoption and ongoing management.

Segment Sub-Segment Largest Segment Fastest Growing
Type Hormonal IUD, Copper IUD Hormonal IUD Hormonal IUD
Distribution Channel Hospital, Gynecology Clinics, Community Health Care Centers, Others Hospital Gynecology Clinics
Competitive Landscape

Competitive Landscape and Market Positioning

Leading companies in the intrauterine devices market:

1. Bayer AG (Germany)

2. CooperSurgical Inc. (United States)

3. Pregna International Limited (India)

4. EUROGINE S.L. (Spain)

5. OCON Medical Ltd. (Israel)

6. Mona Lisa N.V. (Belgium)

7. SMB Corporation of India (India)

8. AbbVie Inc. (United States)

9. DKT International (United States)

10. Prosan International BV (Netherlands)

The intrauterine devices market is advancing with improvements in contraceptive design and long-term effectiveness. Continuous innovation is enhancing safety, comfort, and ease of use. New product introductions are addressing diverse reproductive health needs across populations. The intrauterine devices market is growing with increased adoption of reliable and minimally invasive contraceptive solutions.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
No companies available.
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
Society for Family Health May-26 Society for Family Health, in collaboration with the Oyo State Primary Health Care Board, conducted a dissemination meeting for the SHINE Research initiative focused on scaling hormonal intrauterine devices. The program evaluated implementation outcomes and strategies to expand access to hormonal IUDs in emerging markets.
Bayer AG Aug-22 Bayer AG received FDA approval for a supplemental new drug application extending the use duration of its Mirena IUD to up to eight years. The approval strengthens its long-acting contraceptive portfolio and enhances product lifecycle positioning within the hormonal intrauterine device segment.
Medicines360 Jan-24 Medicines360 partnered with DKT WomanCare to expand access to AVIBELA, a hormonal intrauterine device with high contraceptive effectiveness. The collaboration focuses on improving distribution, affordability, and awareness of long-acting reversible contraceptive options across global markets.
Pregna International Limited Jun-23 Pregna International Limited secured a USD 16 million private equity investment from India Life Sciences Fund III managed by InvAscent. The funding is intended to support expansion and development of women’s reproductive health solutions, including intrauterine device offerings.
Sebela Pharmaceuticals Feb-25 Sebela Pharmaceuticals received FDA approval for MIUDELLA, a contraceptive product indicated for pregnancy prevention in females of reproductive potential for up to three years. The approval expands the company’s reproductive health portfolio and strengthens its position in the long-acting contraceptive market.
Bayer Nov-23 Bayer entered a collaboration and licensing agreement with CrossBay Medical Inc. to develop a single-handed inserter integrated with its hormonal intrauterine system portfolio. The initiative aims to improve device usability for healthcare providers and enhance product differentiation in the IUD market.
CooperSurgical, Inc. Sep-24 CooperSurgical introduced a new single-hand inserter for Paragard, a hormone-free copper intrauterine device. The device launch improves ease of placement for clinicians and strengthens the usability and procedural efficiency of non-hormonal IUD insertion systems.
Medicines360 Mar-22 Medicines360, Population Services International, and Society for Family Health launched Avibela (levonorgestrel-releasing IUS) in Nigeria. The initiative expanded access to hormonal intrauterine contraception in West Africa through coordinated distribution and public health partnerships.
Medicines360 Aug-21 Medicines360, Population Services International, and Society for Family Health launched Avibela (levonorgestrel-releasing IUS) in Kenya. The rollout supported expansion of long-acting reversible contraceptive access in East Africa through multi-stakeholder public health collaboration.
Society for Family Health May-26 Society for Family Health, in collaboration with health authorities and partners, conducted an end-of-project dissemination for the SHINE initiative focused on scaling hormonal intrauterine devices. The program evaluated implementation outcomes and supported evidence generation for expanding access to hormonal IUDs in emerging healthcare markets.
Sebela Pharmaceuticals Feb-25 The U.S. FDA approved Sebela Pharmaceuticals’ MIUDELLA intrauterine system for pregnancy prevention for up to three years. This regulatory approval expands the company’s hormonal IUD portfolio and strengthens its competitive position in long-acting reversible contraceptive solutions within the U.S. reproductive health market.
Medicines360 Jan-24 Medicines360 and DKT WomanCare partnered to expand access to the AVIBELA hormonal intrauterine device across global markets. The collaboration focuses on improving affordability, distribution reach, and awareness of long-acting reversible contraception, strengthening supply availability in underserved reproductive health segments.
Bayer AG Nov-23 Bayer and CrossBay Medical entered a licensing and development agreement to create a single-handed inserter for Bayer’s hormonal intrauterine system portfolio. The initiative enhances usability for healthcare providers and strengthens Bayer’s competitive positioning through improved device delivery and procedural efficiency in IUD administration.
Pregna International Limited Jun-23 Pregna International Limited secured a USD 16 million private equity investment from India Life Sciences Fund III managed by InvAscent. The funding is intended to support expansion in women’s reproductive health product development and scale manufacturing and commercialization capabilities for intrauterine device solutions across global markets.
Bayer AG Aug-22 Bayer received FDA supplemental approval extending the use duration of its Mirena intrauterine device to up to eight years. This regulatory update strengthens product lifecycle positioning and enhances long-term competitiveness in the hormonal IUD segment by expanding patient usage flexibility and clinical adoption potential.
CooperSurgical Inc. Sep-24 CooperSurgical introduced a new single-hand inserter for its Paragard copper intrauterine device. The device is designed to improve procedural ease and placement efficiency in clinical settings, supporting enhanced usability for healthcare providers and reinforcing adoption of hormone-free IUD solutions in contraceptive care.
Report Customization

Explore This Report

Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.

1 report.custom report.segments 2 Custom TOC 3 Related Reports

Intrauterine Devices Market — Custom Segments

Segment Sub-Segment
No segment data available.

Intrauterine Devices Market — report.custom

Custom Chapter Custom Details
No custom TOC data available.

Need a different cut of the data?

Request Custom Research
report.faq_name

What is the market valuation of intrauterine devices?

In 2026 the market for intrauterine devices is worth approximately USD 6.86 billion.

What is the forecasted size of the intrauterine devices industry?

Intrauterine Devices Market size is forecast to climb from USD 6.65 billion in 2025 to USD 9.66 billion by 2035 expanding at a CAGR of over 3.8% during 2026-2035.

How are government family planning programs driving adoption of intrauterine devices?

Government initiatives are increasing access to IUDs through public healthcare systems and subsidized services. This institutional support strengthens adoption by embedding devices into routine reproductive care and expanding clinical availability across broader populations.

How is innovation in hormone-free IUDs influencing market demand?

Development of hormone-free IUDs is expanding user acceptance among women seeking non-hormonal contraception. This increases provider choice at the point of care and supports broader market penetration through more personalized contraceptive options.

Why do hormonal IUDs lead the intrauterine devices market?

Hormonal IUD held a 70.07% share in 2025, supported by widespread clinical familiarity and strong demand for reliable, long-acting, reversible contraception requiring minimal ongoing patient involvement.

Why are gynecology clinics the fastest-growing distribution channel for intrauterine devices?

Gynecology clinics are growing fastest because they provide specialized contraceptive counseling, insertion, and follow-up services, offering streamlined access that aligns well with routine IUD care and patient management.

Why does North America hold the largest share of the intrauterine devices market?

North America leads due to established reproductive healthcare services, broad access to trained providers, and strong adoption of long-acting reversible contraception through clinical care settings.

What factors are driving intrauterine devices market growth in Asia Pacific?

Asia Pacific is projected to expand at a 4.33% CAGR, driven by improving women's healthcare access, wider contraceptive adoption, and expanding provider networks supporting family planning services.

Which companies dominate the intrauterine devices landscape?

Prominent players in the intrauterine devices market include Bayer AG (Germany), CooperSurgical Inc. (United States), Pregna International Limited (India), EUROGINE, S.L. (Spain), OCON Medical Ltd. (Israel), Mona Lisa N.V. (Belgium), SMB Corporation of India (India), AbbVie Inc. (United States), DKT International (United States), Prosan International BV (Netherlands).
Testimonials

Our Clients

"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."

Quality Assurance Manager

"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."

R&D Manager

"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."

Senior Marketing Manager
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →